Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Researchers develop an integrated technology for seeing into cells at greater detail

Invading cells' private space - prying into their internal functions, decisions and communications - could be a powerful tool that may help researchers develop new immunotherapy treatment for cancer.

12 Aug 2020

Study of 300 COVID-19 patients shows efficacy of convalescent plasma therapy

A preliminary analysis of an ongoing study of more than 300 COVID-19 patients treated with convalescent plasma therapy at Houston Methodist suggests the treatment is safe and effective.

12 Aug 2020

Research looks at convalescent plasma use in COVID-19 mouse model

A new study by researchers at the University of Iowa and published on the preprint server bioRxiv in August 2020 reports the utility of a mouse model that recapitulates several aspects of human COVID-19 and can reflect the antiviral efficacy of new drugs as well.

12 Aug 2020

Mouse study shows potential new way to unlock the power of immunotherapy for cancer patients

Immunotherapy has revolutionized cancer treatment by stimulating the patient's own immune system to attack cancer cells, yielding remarkably quick and complete remission in some cases. But such drugs work for less than a quarter of patients because tumors are notoriously adept at evading immune assault.

11 Aug 2020

Focusing on human enzymes and not SARS-CoV-2 could help treat COVID-19

Now, breakthrough research into malaria suggests targeting enzymes from the human host, rather than from the pathogen itself. The new research could pave the way for effective treatments for a wide range of infectious diseases, including the coronavirus disease (COVID-19).

11 Aug 2020

1st human data for Sinovac's SARS-CoV-2 CoronaVac vaccine is out

A group of Chinese researchers recently conducted a phase 2 clinical trial to further evaluate the immunogenicity and safety of SARS-CoV-2 inactivated vaccine known as CoronaVac. The results are currently available on the medRxiv preprint server and demonstrate that the vaccine is well tolerated and without any notable dose-related safety concerns, which opens the door for phase 3 clinical trial.

11 Aug 2020

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

A recent study by researchers from China, available on the bioRxiv preprint server, shows how stable neutralizing nanobody Nb11-59 might be a promising prophylactic and therapeutic molecule against coronavirus disease (COVID-19) – especially if administered via the inhalatory route.

11 Aug 2020

Research looks at how long SARS-CoV-2 antibodies last

A new study by researchers at the Fred Hutchinson Cancer Research Center and the University of Washington and published on the preprint server medRxiv* in August 2020 deals with the changes in neutralizing antibodies in the following months.

11 Aug 2020

SARS-CoV-2 infection and transmission possible in North American deer mice

The current COVID-19 pandemic began as a zoonosis in China, at the end of 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel betacoronavirus with significant similarity to an earlier virus of the same family.

11 Aug 2020

NIH supports research on how pathogens evolve

For several years, physicist John Barton at the University of California, Riverside, has been working on developing models to understand and predict how pathogens, such as HIV, evolve. This research pursuit has just received support from the National Institutes of Health.

10 Aug 2020

Baylor Scott & White Research Institute enrolls first patients in NIH ACTIV-3 clinical trial

On Wednesday, August 5, in Dallas, just one day after the initiative was launched by the National Institutes of Health, Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.

10 Aug 2020

People may have a pre-existing immune response to COVID-19 thanks to common colds

Now, a new study shows that some people have immune responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, thanks to how the body reacted the last time it caught a cold. This means that even if a person has not been exposed to the novel coronavirus, the body has a memory of it and can trigger an immune response to fight the infection.

10 Aug 2020

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.

10 Aug 2020

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.

10 Aug 2020

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.

9 Aug 2020

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.

9 Aug 2020

Nanomedicine-based strategy enhances anti-PD1 therapy to eradicate PTEN-negative GBM

A nanomedicine-based strategy for chemo-immunotherapy (CIT) of glioblastoma (GBM), which has the worst prognosis among brain tumors, was successfully developed.

7 Aug 2020

Study identifies five immune response markers that may predict COVID-19 patient outcomes

Galit Alter, PhD, Group Leader at the Ragon Institute of MGH, MIT and Harvard and Professor of Medicine at Harvard Medical School, and Helen Chu, MD, Associate Professor of Medicine, Division of Allergy and Infectious Diseases, University of Washington School of Medicine, and UW Medicine physician, have recently published a paper which identifies five immune response markers which, collectively, were able to correctly classify both convalescent COVID-19 patients and those who did not survive the disease.

7 Aug 2020

Advanced analysis offers new insights into immune system’s role in severe COVID-19

By conducting advanced analyses of immune system activation in patients with severe COVID-19, researchers at Karolinska Institutet have managed to identify several cell types that play a key part in the immune response to the new coronavirus and the hyperinflammation seen in severe cases of the disease.

7 Aug 2020

Nanoparticle method captures and measures common marker of heart disease

Researchers at the University of Wisconsin-Madison have developed a method combining sticky nanoparticles with high-precision protein measurement to capture and analyze a common marker of heart disease to reveal details that were previously inaccessible.

7 Aug 2020